Hisham Mehanna1, Taleb Al-Maqbili, Ben Carter, Emma Martin, Nicholas Campain, John Watkinson, Chris McCabe, Kristien Boelaert, Jayne A Franklyn. 1. Institute of Head and Neck Studies and Education, School of Cancer Sciences (H.M., T.A., N.C.), University of Birmingham, Birmingham B15 2TT, United Kingdom; Cancer Research Clinical Trials Unit, School of Cancer Sciences (B.C., E.M.), University of Birmingham, Birmingham B15 2TT, United Kingdom; University Hospitals Birmingham NHS Foundation Trust (J.W.), University of Birmingham, Birmingham B15 2TT, United Kingdom; and School of Clinical and Experimental Medicine (C.M., K.B., J.A.F.), University of Birmingham, Birmingham B15 2TT, United Kingdom.
Abstract
CONTEXT: There is controversy as to whether papillary thyroid microcarcinoma (PTMC) represents more than one disease entity with different outcomes, requiring different treatment. OBJECTIVES: To compare characteristics, outcomes, and factors associated with prognosis of incidental and nonincidental PTMC. SETTING AND DESIGN: Two reviewers performed searches of online databases (1966-2012), reference lists, and conference abstract books. Longitudinal studies of subjects >16 years old receiving any treatments for papillary thyroid cancer ≤10 mm in size were included. Two reviewers independently screened abstracts and articles, extracted data, and assessed quality of studies using National Institute of Clinical Excellence and PRISMA criteria. RESULTS: Of 1102 abstracts identified, 262 studies were reviewed and 17 studies included, comprising 3523 subjects, with mean follow-up of 70 months and total follow-up of 21 329 person-years. This included 854 subjects with incidental PTMC (follow-up, 4800 person-years; mean tumor size, 4.6 mm [range 3.3-6.7 mm]) and 2669 nonincidental PTMC cases (follow-up, 16 529 person-years; mean tumor size, 6.9 mm [range 5.6-8.0 mm]). The recurrence rate in the incidental group (0.5%; 95% confidence interval [CI], 0-1%, P < .001) was significantly lower than that in the nonincidental group PTMC (7.9%; 95% CI, 5-11%), with an OR of recurrence of 14.7 (95% CI, 5.6-54.8, P < .001) for nonincidental PTMC, compared with incidental PTMC. Lymph nodes were involved in 80% (126/157) of recurrences. On meta-regression, age, sex, size, tumor multifocality, lymph node involvement, and treatment modality were not significantly associated with recurrence. CONCLUSIONS: Our meta-analysis strongly suggests the existence of at least two distinct entities of PTMC. Incidental PTMC has different clinical characteristics and a much lower recurrence rate than nonincidental PTMC, suggesting that management protocols should be re-considered. Additional studies with standardized data collection are required to explore potential differences between subgroups of nonincidental PTMC.
CONTEXT: There is controversy as to whether papillary thyroid microcarcinoma (PTMC) represents more than one disease entity with different outcomes, requiring different treatment. OBJECTIVES: To compare characteristics, outcomes, and factors associated with prognosis of incidental and nonincidental PTMC. SETTING AND DESIGN: Two reviewers performed searches of online databases (1966-2012), reference lists, and conference abstract books. Longitudinal studies of subjects >16 years old receiving any treatments for papillary thyroid cancer ≤10 mm in size were included. Two reviewers independently screened abstracts and articles, extracted data, and assessed quality of studies using National Institute of Clinical Excellence and PRISMA criteria. RESULTS: Of 1102 abstracts identified, 262 studies were reviewed and 17 studies included, comprising 3523 subjects, with mean follow-up of 70 months and total follow-up of 21 329 person-years. This included 854 subjects with incidental PTMC (follow-up, 4800 person-years; mean tumor size, 4.6 mm [range 3.3-6.7 mm]) and 2669 nonincidental PTMC cases (follow-up, 16 529 person-years; mean tumor size, 6.9 mm [range 5.6-8.0 mm]). The recurrence rate in the incidental group (0.5%; 95% confidence interval [CI], 0-1%, P < .001) was significantly lower than that in the nonincidental group PTMC (7.9%; 95% CI, 5-11%), with an OR of recurrence of 14.7 (95% CI, 5.6-54.8, P < .001) for nonincidental PTMC, compared with incidental PTMC. Lymph nodes were involved in 80% (126/157) of recurrences. On meta-regression, age, sex, size, tumor multifocality, lymph node involvement, and treatment modality were not significantly associated with recurrence. CONCLUSIONS: Our meta-analysis strongly suggests the existence of at least two distinct entities of PTMC. Incidental PTMC has different clinical characteristics and a much lower recurrence rate than nonincidental PTMC, suggesting that management protocols should be re-considered. Additional studies with standardized data collection are required to explore potential differences between subgroups of nonincidental PTMC.
Authors: Michal Mekel; Hayim Gilshtein; Abbas Al-Kurd; Bishara Bishara; Michael M Krausz; Herbert R Freund; Yoram Kluger; Ahmed Eid; Haggi Mazeh Journal: World J Surg Date: 2016-01 Impact factor: 3.352
Authors: Min Gyeong Cheon; Ye Won Son; Joon-Hyop Lee; Ho Hee Jang; Yoo Seung Chung Journal: Cancer Genomics Proteomics Date: 2019 Sep-Oct Impact factor: 4.069
Authors: Bin Xu; Tihana Ibrahimpasic; Laura Wang; Mona M Sabra; Jocelyn C Migliacci; R Michael Tuttle; Ian Ganly; Ronald Ghossein Journal: Thyroid Date: 2016-09-07 Impact factor: 6.568
Authors: A Maturo; L Tromba; L De Anna; G Carbotta; G Livadoti; C Donello; F Falbo; G Galiffa; Antonella Esposito; A Biancucci; S Carbotta Journal: G Chir Date: 2017 Mar-Apr
Authors: F Cecoli; E M Ceresola; V Altrinetti; M Cabria; M Cappagli; A Montepagani; C M Cuttica; U Filippi; D Saverino; M Raffa; M Caputo; F Minuto; M Giusti; M Bagnasco Journal: Eur Thyroid J Date: 2016-06-02
Authors: Krzysztof Kaliszewski; Beata Wojtczak; Marta Strutyńska-Karpińska; Tadeusz Łukieńczuk; Zdzisław Forkasiewicz; Paweł Domosławski Journal: Oncol Lett Date: 2016-05-30 Impact factor: 2.967